Cutaneous short-interfering RNA therapy.
Since the 1990s, RNA interference (RNAi) has become a major subject of interest, not only as a tool for biological research, but also, more importantly, as a therapeutic approach for gene-related diseases. The use of short-interfering RNAs (siRNAs) for the sequence-specific knockdown of disease-causing genes has led to numerous preclinical and even a few clinical studies. Applications for cutaneous delivery of therapeutic siRNA are now emerging owing to a strong demand for effective treatments of various cutaneous disorders. Although successful studies have been performed using several different delivery techniques, most of these techniques encounter limitations for translation to the clinic with regards to patient compliance. This review describes the principal findings and applications in cutaneous RNAi therapy and focuses on the promises and pitfalls of the delivery systems.
Geusens
B
B
Ghent University Hospital, Department of Dermatology, De Pintelaan 185, B-9000 Ghent, Belgium. Barbara.Geusens@ugent.be
Sanders
N
N
Prow
T
T
Van Gele
M
M
Lambert
J
J
D000279:Administration, Cutaneous; D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D010349:Patient Compliance; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use*; D012867:Skin / Q000378:metabolism; D012871:Skin Diseases / Q000628:therapy*
D034741:RNA, Small Interfering